CORT Corcept Therapeutics Inc
Price (delayed)
$54.85
Market cap
$5.79B
P/E Ratio
40.63
Dividend/share
N/A
EPS
$1.35
Enterprise value
$5.67B
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym®
Highlights
The revenue rose by 40% year-on-year and by 7% since the previous quarter
The gross profit is up by 40% year-on-year and by 7% since the previous quarter
The P/E is 64% more than the 5-year quarterly average of 24.8 and 35% more than the last 4 quarters average of 30.0
The quick ratio is down by 21% year-on-year and by 11% since the previous quarter
Key stats
What are the main financial stats of CORT
Market
Valuations
Earnings
Shares outstanding
105.5M
Market cap
$5.79B
Enterprise value
$5.67B
Price to earnings (P/E)
40.63
Price to book (P/B)
8.46
Price to sales (P/S)
8.39
EV/EBIT
41.82
EV/EBITDA
41.42
EV/Sales
8.39
Revenue
$675.04M
Gross profit
$664.16M
Operating income
$136.95M
Net income
$139.73M
EBIT
$135.48M
EBITDA
$136.81M
Free cash flow
$195.9M
Per share
Balance sheet
Liquidity
EPS
$1.35
EPS diluted
$1.23
Free cash flow per share
$1.9
Book value per share
$6.49
Revenue per share
$6.54
TBVPS
$8.14
Total assets
$840.55M
Total liabilities
$160.96M
Debt
$6.94M
Equity
$679.59M
Working capital
$330.83M
Debt to equity
0.01
Current ratio
3.35
Quick ratio
3.11
Net debt/EBITDA
-0.88
Margins
Efficiency
Dividend
EBITDA margin
20.3%
Gross margin
98.4%
Net margin
20.7%
Operating margin
20.3%
Return on assets
18.7%
Return on equity
22.7%
Return on invested capital
27%
Return on capital employed
19.4%
Return on sales
20.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CORT stock price
How has the Corcept Therapeutics stock price performed over time
Intraday
-0.27%
1 week
1.01%
1 month
-25.49%
1 year
126.65%
YTD
8.85%
QTD
8.85%
Financial performance
How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$675.04M
Gross profit
$664.16M
Operating income
$136.95M
Net income
$139.73M
Gross margin
98.4%
Net margin
20.7%
The revenue rose by 40% year-on-year and by 7% since the previous quarter
The gross profit is up by 40% year-on-year and by 7% since the previous quarter
CORT's net income is up by 32% YoY
Corcept Therapeutics's operating income has increased by 28% YoY but it has decreased by 4.5% from the previous quarter
Growth
What is Corcept Therapeutics's growth rate over time
Valuation
What is Corcept Therapeutics stock price valuation
P/E
40.63
P/B
8.46
P/S
8.39
EV/EBIT
41.82
EV/EBITDA
41.42
EV/Sales
8.39
The P/E is 64% more than the 5-year quarterly average of 24.8 and 35% more than the last 4 quarters average of 30.0
The EPS has grown by 32% year-on-year
The stock's price to book (P/B) is 57% more than its 5-year quarterly average of 5.4 and 32% more than its last 4 quarters average of 6.4
The company's equity rose by 34% YoY and by 6% QoQ
The revenue rose by 40% year-on-year and by 7% since the previous quarter
CORT's P/S is 31% above its 5-year quarterly average of 6.4 and 29% above its last 4 quarters average of 6.5
Efficiency
How efficient is Corcept Therapeutics business performance
CORT's ROIC is down by 22% year-on-year and by 14% since the previous quarter
The return on sales has declined by 11% since the previous quarter and by 9% year-on-year
CORT's return on assets is down by 7% since the previous quarter but it is up by 4.5% year-on-year
The return on equity has declined by 7% since the previous quarter but it is up by 3.2% year-on-year
Dividends
What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CORT.
Financial health
How did Corcept Therapeutics financials performed over time
The total liabilities has grown by 40% YoY and by 11% from the previous quarter
The company's total assets rose by 35% YoY and by 7% QoQ
Corcept Therapeutics's debt is 99% lower than its equity
The company's equity rose by 34% YoY and by 6% QoQ
Corcept Therapeutics's debt has increased by 2.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.